{"id":28302,"date":"2024-07-26T15:21:00","date_gmt":"2024-07-26T15:21:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/4470577_AE70577_0"},"modified":"2024-07-26T15:21:00","modified_gmt":"2024-07-26T15:21:00","slug":"pierre-fabre-laboratories-receives-chmp-positive-opinion-for-braftovi-encorafenib-in-combination-with-mektovi-binimetinib-for-the-treatment-of-adult-patients-with-advanced-non-small-ce","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=28302","title":{"rendered":"Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI\u00ae (encorafenib) in combination with MEKTOVI\u00ae (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation"},"content":{"rendered":"<ul type=\"disc\">\n<li><i>The positive&nbsp;CHMP opinion is based on results from the Phase II PHAROS trial,<sup>[<\/sup><sup>1]<\/sup> which demonstrated an objective response rate (ORR) of<\/i>&nbsp;<i>75% in treatment-na\u00efve patients and 46% in previously treated patients.<\/i>&nbsp;<i>The safety profile is consistent with that observed in the approved metastatic melanoma indication<sup>[<\/sup><sup>1]<\/sup><\/i><\/li>\n<li><i>The European Commission decision for BRAFTOVI<sup>\u00ae<\/sup> (encorafenib) + MEKTOVI<sup>\u00ae<\/sup> (binimetinib) is expected later this year.<\/i><\/li>\n<\/ul>\n<p>CASTRES, <span class=\"xn-location\">France<\/span>, <span class=\"xn-chron\">July 26, 2024<\/span> \/PRNewswire\/ &#8212; Pierre Fabre Laboratories announced today that the Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the approval of BRAFTOVI<sup>\u00ae <\/sup>(encorafenib) in combination with MEKTOVI<sup>\u00ae<\/sup> (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a <i>BRAF<sup>V600E<\/sup> <\/i>mutation. The positive opinion will now be submitted to the European Commission (EC) with a decision on EU marketing authorisation (MA) expected later this year.<\/p>\n<p><span class=\"xn-person\">Eric Ducournau<\/span>, Chief Executive Officer, Pierre Fabre Laboratories said: &#8220;<i>The positive CHMP opinion marks a pivotal step in our commitment to delivering an additional effective targeted treatment option for patients with advanced NSCLC with a <\/i><i>BRAF<sup>V600E<\/sup><\/i><i>&nbsp;mutation, who at present have limited treatment options. We look forward to the European Commission&#8217;s decision to make BRAFTOVI<sup>\u00ae<\/sup> + MEKTOVI<sup>\u00ae<\/sup> available to non-small cell lung cancer patients in <span class=\"xn-location\">Europe<\/span><\/i>.&#8221;<\/p>\n<p>The CHMP positive opinion is supported by data from the global, open-label, multicentre, non-randomised Phase II PHAROS trial, which included 98 patients from 56 study centres across 5 countries.<sup>[<\/sup><sup>1]<\/sup><\/p>\n<p>At primary analysis (cut-off date: <span class=\"xn-chron\">September 22, 2022<\/span>), the primary endpoint of the trial (objective response rate [ORR] determined by independent radiology review [IRR]) was met. The PHAROS trial showed that in patients with advanced NSCLC with a <i>BRAF<sup>V600E<\/sup> <\/i>mutation, BRAFTOVI<sup>\u00ae<\/sup> and MEKTOVI<sup>\u00ae<\/sup> provided a meaningful clinical benefit with an ORR of 75% (95% CI: 62, 85) in treatment na\u00efve patients (n=59), with 59% of them maintaining their&nbsp;response for at least 12 months. For those patients who had received prior therapy (n=39), the ORR was 46% (95% CI: 30, 63), with 33% maintaining their response for at least 12 months.<sup>[<\/sup><sup>1]<\/sup><\/p>\n<p>CONTACT: Laurence MARCHAL <a href=\"mailto:laurence.marchal@pierre-fabre.com\" target=\"_blank\" rel=\"nofollow noopener\">laurence.marchal@pierre-fabre.com<\/a><\/p>\n<div id=\"prni_dvprnejpg2988left\" dir=\"ltr\"> <a href=\"https:\/\/mma.prnasia.com\/media2\/2416854\/Pierre_Fabre_Laboratories.jpg?p=medium600\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" id=\"prnejpg2988left\" title src=\"https:\/\/mma.prnasia.com\/media2\/2416854\/Pierre_Fabre_Laboratories.jpg?p=medium600\" alt align=\"middle\"><\/a> <br \/><span><\/span> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>The positive&nbsp;CHMP opinion is based on results from the Phase II PHAROS trial,[1] which demonstrated an objective response rate (ORR) of&nbsp;75% in treatment-na\u00efve patients and 46% in previously treated patients.&nbsp;The safety profile is consistent with that observed in the approved metastatic melanoma indication[1] The European Commission decision for BRAFTOVI\u00ae (encorafenib) + MEKTOVI\u00ae (binimetinib) is expected [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":28303,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-28302","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI\u00ae (encorafenib) in combination with MEKTOVI\u00ae (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=28302\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI\u00ae (encorafenib) in combination with MEKTOVI\u00ae (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation - My Blog\" \/>\n<meta property=\"og:description\" content=\"The positive&nbsp;CHMP opinion is based on results from the Phase II PHAROS trial,[1] which demonstrated an objective response rate (ORR) of&nbsp;75% in treatment-na\u00efve patients and 46% in previously treated patients.&nbsp;The safety profile is consistent with that observed in the approved metastatic melanoma indication[1] The European Commission decision for BRAFTOVI\u00ae (encorafenib) + MEKTOVI\u00ae (binimetinib) is expected [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=28302\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-26T15:21:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnasia.com\/media2\/2416854\/Pierre_Fabre_Laboratories.jpg?p=medium600\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=28302#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=28302\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI\u00ae (encorafenib) in combination with MEKTOVI\u00ae (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation\",\"datePublished\":\"2024-07-26T15:21:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=28302\"},\"wordCount\":362,\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=28302#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/pierre-fabre-laboratories-receives-chmp-positive-opinion-for-braftovi-encorafenib-in-combination-with-mektovi-binimetinib-for-the-treatment-of-adult-patients-with-advanced-non-small-ce.jpg\",\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=28302\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=28302\",\"name\":\"Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI\u00ae (encorafenib) in combination with MEKTOVI\u00ae (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=28302#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=28302#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/pierre-fabre-laboratories-receives-chmp-positive-opinion-for-braftovi-encorafenib-in-combination-with-mektovi-binimetinib-for-the-treatment-of-adult-patients-with-advanced-non-small-ce.jpg\",\"datePublished\":\"2024-07-26T15:21:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=28302#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=28302\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=28302#primaryimage\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/pierre-fabre-laboratories-receives-chmp-positive-opinion-for-braftovi-encorafenib-in-combination-with-mektovi-binimetinib-for-the-treatment-of-adult-patients-with-advanced-non-small-ce.jpg\",\"contentUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/pierre-fabre-laboratories-receives-chmp-positive-opinion-for-braftovi-encorafenib-in-combination-with-mektovi-binimetinib-for-the-treatment-of-adult-patients-with-advanced-non-small-ce.jpg\",\"width\":599,\"height\":355},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=28302#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI\u00ae (encorafenib) in combination with MEKTOVI\u00ae (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI\u00ae (encorafenib) in combination with MEKTOVI\u00ae (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=28302","og_locale":"en_US","og_type":"article","og_title":"Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI\u00ae (encorafenib) in combination with MEKTOVI\u00ae (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation - My Blog","og_description":"The positive&nbsp;CHMP opinion is based on results from the Phase II PHAROS trial,[1] which demonstrated an objective response rate (ORR) of&nbsp;75% in treatment-na\u00efve patients and 46% in previously treated patients.&nbsp;The safety profile is consistent with that observed in the approved metastatic melanoma indication[1] The European Commission decision for BRAFTOVI\u00ae (encorafenib) + MEKTOVI\u00ae (binimetinib) is expected [&hellip;]","og_url":"https:\/\/transmediavictoria.net.au\/?p=28302","og_site_name":"My Blog","article_published_time":"2024-07-26T15:21:00+00:00","og_image":[{"url":"https:\/\/mma.prnasia.com\/media2\/2416854\/Pierre_Fabre_Laboratories.jpg?p=medium600","type":"","width":"","height":""}],"author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=28302#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=28302"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI\u00ae (encorafenib) in combination with MEKTOVI\u00ae (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation","datePublished":"2024-07-26T15:21:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=28302"},"wordCount":362,"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=28302#primaryimage"},"thumbnailUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2024\/07\/pierre-fabre-laboratories-receives-chmp-positive-opinion-for-braftovi-encorafenib-in-combination-with-mektovi-binimetinib-for-the-treatment-of-adult-patients-with-advanced-non-small-ce.jpg","articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=28302","url":"https:\/\/transmediavictoria.net.au\/?p=28302","name":"Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI\u00ae (encorafenib) in combination with MEKTOVI\u00ae (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"primaryImageOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=28302#primaryimage"},"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=28302#primaryimage"},"thumbnailUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2024\/07\/pierre-fabre-laboratories-receives-chmp-positive-opinion-for-braftovi-encorafenib-in-combination-with-mektovi-binimetinib-for-the-treatment-of-adult-patients-with-advanced-non-small-ce.jpg","datePublished":"2024-07-26T15:21:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=28302#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=28302"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/transmediavictoria.net.au\/?p=28302#primaryimage","url":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2024\/07\/pierre-fabre-laboratories-receives-chmp-positive-opinion-for-braftovi-encorafenib-in-combination-with-mektovi-binimetinib-for-the-treatment-of-adult-patients-with-advanced-non-small-ce.jpg","contentUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2024\/07\/pierre-fabre-laboratories-receives-chmp-positive-opinion-for-braftovi-encorafenib-in-combination-with-mektovi-binimetinib-for-the-treatment-of-adult-patients-with-advanced-non-small-ce.jpg","width":599,"height":355},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=28302#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI\u00ae (encorafenib) in combination with MEKTOVI\u00ae (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/28302","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=28302"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/28302\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/media\/28303"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=28302"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=28302"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=28302"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}